Richard Pittner, PhD - bio image

Richard Pittner, PhD

Vice President of Discovery Biology

Back to Team

Dr. Pittner joined Escient Pharmaceuticals as Vice President of Discovery Biology in May 2018. He was previously a consultant for Escient and active as a startup advisor and technology incubator in San Diego. Dr. Pittner co-founded OXT-Therapeutics in 2016 as Chief Development Officer, focused on the development of an oxytocin-based portfolio for metabolic disease. Previously, he co-founded an incubator group, BioShore Partners in 2015, which progressed 2 product concepts in 2016-2017 into newly incorporated startups – Abvance and Aquros. Since 2014, Dr. Pittner has been an advisor (acting SVP) to CPC/Xinbang in evaluating/in-licensing peptide therapeutic programs for the Chinese market. From 2010-2013 he was at Pfizer and then Eli Lilly where he led External R&D efforts, identifying, evaluating and in-licensing external drug assets. Up until 2007, he spent 15 years at Amylin Pharmaceuticals as Head of Discovery Biology developing nov-el peptide therapeutics for metabolic diseases (including Byetta and Symlin). He holds a number of patents, is the co-author of over 40 publications and received his PhD in Biochemistry from University of Nottingham in 1985 before becoming an Assistant Pro-fessor of Physiology at LSU Medical Center in New Orleans in 1990.